

Commission of Canada Commission de la santé mentale du Canada

Value and efficacy: Expanding access to counselling, psychotherapies and psychological services

✓ @MHCC_ f /theMHCC in /Mental Health Commission of Canada
 ✓ @theMHCC / 1MHCC

September 26, 2017



Commission of Canada Commission de la santé mentale du Canada

Moderator:







 Mental Health Commission of Canada Commission de la santé mentale du Canada

Speakers:



Dr. Helen-Maria Vasiliadis

Professor and Researcher, Faculty of Medicine and Health Sciences, University of Sherbrooke



Dr. Giorgio Tasca Associate Professor, School of Psychology, University of Ottawa

The Evidence-Base for Psychotherapy

Giorgio A. Tasca, Ph.D. Associate Professor School of Psychology University of Ottawa





Goals for Today

- To evaluate the evidence base for psychotherapies and evidence-based practices in psychotherapy
- To critically evaluate the relative efficacy of medications versus psychotherapy for depressive disorders.
- To evaluate the merits of common factors in predicting psychotherapy outcomes

Definition of Psychotherapy

- The informed and intentional application of clinical methods and interpersonal stances
- Derived from established psychological principles
- For the purpose of assisting people to modify their behaviors, cognitions, emotions, and/or other personal characteristics

American Psychological Association (2012)

Psychotherapy Research

DEFINITIONS

Empirically Supported Treatments

- List of empirically supported treatments by Division of Clinical Psychology, APA
 - First published list: Chambless & Hollon (1998)
 - <u>https://www.div12.org/psychological-treatments/</u>
- Criteria
 - Two RCTs from different locations or research teams
 - Treatment manuals, assessed treatment fidelity
 - Clearly defined sample and disorder
 - Clearly superior to a placebo/control or to another bona fide treatment

Evidence-Based Practice in Psychotherapy (APA, 2006)

- Integration of:
 - Best available research, with
 - Clinical expertise, in the context of
 - Patient characteristics, culture and preferences
 - <u>http://www.apa.org/pubs/journals/features/evidence-based-statement.pdf</u>

Psychotherapy Use

- Over 1 million Canadians use psychotherapy in a given year (Cox, 2014; Vasiliadis et al., 2009)
 - > 5% used outpatient services for mental health beyond family practitioner
- Rates of psychotherapy use has been stable or declined in the past decade (Olfson & Marcus, 2010)



Efficacy of Psychotherapy

- Is psychotherapy more effective than no treatment?
- Mega-analyses (meta-analyses of meta-analyses) (Lambert & Bergin, 1994; Grissom, 1996)
 - Reviewed 25 and 68 MA studies respectively looking at psychotherapy vs no-treatment.
 - Average effect size of d=.80: a "large" effect (Wampold & Imel, 2015)
 - i.e., average patient is better off than 79% of untreated controls
 - 69% success rate due to psychotherapy
 - 14% of the outcome variance accounted for
- Effects sizes are as large as or larger than many common medical procedures (Rosnow & Rosenthal, 2003; Wampold et al., 2005; 2007)
 - E.g., interventions in cardiology (e.g. statins), geriatric medicine, asthma, aspirin as a prophylaxis for heart attack, warfarin for blood clots, AZT for neonatal HIV infection, influenza vaccine, cataract surgery....

Types of Psychotherapy

- Interpersonal Psychotherapy (IPT):
 - a brief structured therapy that focuses on interpersonal issues in depression
- Behavioral Activation (BA):
 - raises the patient's awareness of pleasant activities and seeks to increase the patient's positive interactions with the environment;
- Cognitive Behavioral Therapy (CBT):
 - focuses on a patient's negative beliefs, how they affect current and future behavior, and restructures the beliefs;
- Psychodynamic Therapy (PDT):
 - focuses on unresolved conflicts and relationships and the impact they have on a patient's current functioning;

Relative Efficacy of Psychotherapy Approaches

- Are there differences in outcomes between treatment types?
- Mega-analyses of 32 meta-analyses of bona fide treatments (Wampold et al., 1997; 2002; Wampold & Imel, 2015).
 - Differences between therapies yielded an effect size of d= .20
 - a "small" effect accounting for 1% of the variance in the outcome.
 - Results are consistent for anxiety and depression (Wampold et al., 2007; 2008; Wampold & Imel, 2015)
- When researcher allegiance is taken into account, the relative efficacy was negligible: d = 0 to .17 (Lambert & Ogles, 2004; Wampold, 2001).
- Drop out rates are equivalent across treatments (Swift & Greenberg, 2012)
 - 19% in clinical trials, 38% in community practices

Forest Plot



ACT

IPT

behavioural activation

interpersonal therapy

Barth, J., et al. (2013). Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. *PLoS medicine*, *10*(5), e1001454.

Psychotherapy and Antidepressant Medications

- Both psychotherapy and SSRIs are more effective than placebo (de Rubeis et al., 2005)
- Psychotherapy and SSRIs do not differ in effectiveness when bona fide psychotherapies are tested (Spielmans et al., 2011):
 - Chronic vs non-chronic depression (de Maat et al., 2006)
 - Severity of depression (de Cuijpers et al., 2008; Maat et al., 2006)
 - Some evidence for superiority of SSRIs for dysthymia but effects are small (de Cuijpers et al., 2008)
- Psychotherapy has better long term outcomes at follow up (de Maat et al., 2006; Imel et al., 2008; Spielmans et al., 2011)
 - Drop out rates lower for psychotherapy (de Cuijpers et al., 2008)
 - Psychotherapies create less resistance to multiple administrations (Wampold, 2011).
- 75% of Patients prefer psychotherapy to medications for depression (Swift et al., 2013)
 - Client preference is significantly related to outcomes (Swift et al., 2011)
 - Most clients receive medications (Olfson & Marcus, 2010).

"Psychotherapy and Medications are Equally Effective" - Revisited

Publication Bias

- Tendency to publish only significant findings
- Suppression of data by industry or researchers
- Effects of antidepressant medications are likely over estimated (Turner et al., 2008)

"Psychotherapy and Medications are Equally Effective" - Revisited

- 31% of 74 FDA registered trials between 1987-2004 were never published (n = 23)
 - Positive trials 12x more likely to be published (Turner, 2008).
- Effect size of medication:
 - Published trials: d = 0.37
 - Unpublished trials: d = 0.15
 - Adjusted effect size: *d* = 0.25
- Evidence of minimal publication bias in 31 published psychotherapy trials for depression (Niemeyer et al., 2013)
 - Some evidence of publication bias in CBT trials (Cuijpers et al., 2010)
 - Publication bias in NIMH funded psychotherapy studies (Driessen et al., 2017)
 - Adjusted effect sizes for psychotherapy remain larger than adjusted effect size for medications (d = .42)

Common Factors

- Factors that reliably lead to positive outcomes that are:
 1) Inherent in any therapeutic situation, and
 2) Not specific to any one therapy approach.
- <u>Relationship</u>: alliance; client feedback.
- <u>Patient</u>: severity; expectation of benefit/hope (a.k.a., placebo); belief in credibility of therapy and therapist, attachment, preference.
- <u>Therapist</u>: allegiance to the therapeutic approach (belief in effectiveness); empathy; managing countertransference.

Common Factors



Percent of total outcome variance attributable to therapeutic factors (Norcross, 2011)

•80% of NIH dollars for psychosocial intervention research is spent on evaluating efficacy of treatment methods (Norcross, 2012).

Evidence-Based Practices in Psychotherapy

(Norcross, 2011)

Therapeutic alliance (Horvath et al., 2011)

Repairing alliance ruptures (Safran et al., 2011)

Therapist empathy (Elliott et al., 2011)

Managing countertransference (Hayes et al., 2011)

Progress Monitoring (Lambert & Shimokawa, 2011) *r* = .27 with outcomes

r = .24 with outcomes

r = .31 with outcomes

r = .56 with outcomes

r = .25 with outcomes

Common Factors: Relationship

- Therapeutic alliance
 - Defined as agreement on tasks and goals of therapy, and the bond between therapist and patient (Bordin, 1967).
 - Emphasizes conscious aspects of relationship, like collaboration and consensus.
 - Meta-analysis of individual therapy with 200 studies (Horvath et al., 2011).
 - Only included studies with bona fide treatments
 - "Medium" effect of alliance to predict outcome (d = .71)
 - Therapeutic alliance in the early and late sessions was most related to outcomes (middle session alliance was not)
 - No differences between types of psychotherapy (IPT, CBT, STDP, etc.) on the relation between alliance and outcome.
 - Emerging evidence that recognizing and repairing alliance ruptures improves outcomes (Safran et al., 2011).

Common Factors: Patient

- Severity of problems
 - Functional impairment, severity of symptoms associated with poorer outcomes (Clarkin & Levy, 2004).
 - Comorbid personality disorder, and history of sexual abuse also associated with poorer outcome and premature termination (Clarkin & Levy, 2004).
- Expectations/Hope
 - Accounts for a small but significant (r = .21) amount of outcome variance (Constantino, 2011).
- Coping style
 - Match between client coping style and treatment approach related to positive outcomes with a medium effect size (r = .56) (Beutler et al., 2011).
 - Externalizing style with symptom-focused treatment
 - Internalizing style with insight-oriented treatment

Common Factors: Therapist

- Therapist effects
 - Differences between therapists usually account for 7% of outcome variance.
 - 11% to 38% of therapists on average had patients who ended therapy worse off than when they started (Kraus et al., 2011; N = 700 therapists and N = 7,000 patients)
 - Up to 16% of therapists were classified as reliably "harmful"
 - Frequency of effective therapists ranged from 29% to 67% depending on the disorder (Krauss et al., 2011).
- Training therapists to be adherent and competent to a manual is not significantly related to client outcomes (Webb et al., 2010).
 - Adherence (r = .02)
 - Competence (r = .07)
- Characteristics of effective therapists (Wampold et al., 2017)
 - Ability to form an alliance across a range of patients
 - Facilitative interpersonal skills (empathy, verbal/emotional fluency)
 - Professional self doubt (health skepticism about one's abilities)
 - Deliberate practice (individualized continuous training)

Practice-Based Implications

- 1. Psychotherapy is effective for many mental disorders
 - a. As or more effective than anti-depressant medications
 - b. Know the research it instills hope in patients
- 2. Bona-fide psychotherapies are equally effective for many disorders
 - a. Therapies with an established psychological theory of the disorder, and treatment based on the theory, delivered by a trained professional
- 3. Common factors account for a significant proportion of patient outcomes that exceeds the specific therapy offered
 - a. Develop an alliance early and maintain it:
 - a. Recognize and repair an alliance rupture do not ignore it (Safran et al., 2011)
 - b. Alliance growth over time is potentially therapeutic in and of itself (Zilcha-Mano, 2017)
 - b. Therapists engage in deliberate practice:
 - a. Seek the patient's perspective on therapist empathy
 - b. Be aware of very negative effects of therapist: hostility, confrontations, treatment rigidity (countertransference).
 - c. Systematically collect session to session patient outcomes and use this information to adjust treatment.
 - c. Patient factors such as severity, comorbidity, coping style.
 - a. Assess for these and adjust therapy accordingly



- A collaboration between UofT Psychiatry and uOttawa Psychology to conduct practice-based research in psychotherapy
- Recently received a CIHR operating grant to train communitybased therapists to identify and repair alliance ruptures
- Free monthly E-Newsletter that summarizes the best psychotherapy research for clinicians
- Free to join: <u>www.pprnet.ca</u>.

Insuring Psychological Services as part of Medicare is Cost-Effective for Depression in Canada

MHCC WEBINAR

September 26, 2017

Expanding Access to Counselling, Psychotherapies and Psychological Services: Value and Efficacy Confirmation

Helen-Maria Vasiliadis Professor, FMSS, Université de Sherbrooke Researcher, Centre de Recherche – Hôpital Charles-Le Moyne

Centre de santé et de services sociaux Champlain—Charles-Le Moyne

Centre affilié universitaire et régional de la Montérégie

UNIVERSITÉ DE SHERBROOKE



Faculté de médecine et des sciences de la santé

CENTRE DE RECHERCHE - HÔPITAL CHARLES-LE MOYNE



Grant #: MOP 271771.

H-M Vasiliadis, Université de Sherbrooke

Alain Lesage, Université de Montréal

Eric Latimer, McGill University

Martin Drapeau, McGill University

Advisory Committee

- Mental Health Commission of Canada
- Quebec Ministry of Health and Social Services
- Canadian Psychological Association
- Order (College) of Psychologists of Quebec (OPQ) and Ontario
- Community organizations REVIVRE
- Institute of Health Economics

Citation:

Vasiliadis HM, Dezetter A, Latimer E, Drapeau M, Lesage A. Assessing the Costs and Benefits of Insuring Psychological Services as Part of Medicare for Depression in Canada. Psychiatr Serv. 2017;68(9):899-906.

Rationale

- The prevalence of depression is comparable to that of other common chronic diseases like hypertension and diabetes: lifetime rates in Canada reach up to 11.3%. CCHS on MH 2012
- The disability related to depression is ranked as one of the highest among all diseases.^{WHO, 2012}
- The attributable costs associated with depression have increased in North America to reach \$210 billion in 2010. Greenberg et al., 2015
- Close to 50% do not use health services for their depression.^{CCHS, 2002; 2012}
- Modern psychological therapies can cost-effectively supplement or replace pharmacological approaches to treat depression.^{Myhr et} al., 2006; Wells et al., 2007; CANMAT, 1999

Context

- Among Canadians consulting for mental health reasons, close to 80% consult their family physician.^{Vasiliadis et al., 2005}
- The majority of family physicians, the gatekeepers of the health system, are aware of evidence-based psychological therapies but are not trained to offer them, don't have time, or do not wish to offer them.^{Grenier et al., 2008}
 - The largest barrier noted from family physicians for not referring patients who needed psychological services is the lack of public health insurance coverage.
 - As a result, access to service providers of psychotherapy in Canada is both limited and inequitable.

Population based studies

- The Joint Canada US Health Survey (2004), highlighted disparities in treatment-seeking among depressed populations associated with medical insurance in the United States.^{Vasiliadis et al.,}
- CCHS-MHWB (2002) showed that income and education were barriers to consulting psychologists and other health providers. Vasiliadis et al., 2009
- Recent data from the CCHS-MH (2012) showed that ^{Sunderland & Findlay,} ²⁰¹³:
 - 39% of adults with major depression had reported an unmet mental health care need
 - Of which 71% had reported a need for counseling/psychotherapy.

A report carried out by Quebec's Health Commissioner on the performance of the health system clearly highlighted <u>inequity in access to effective mental health services</u> such as psychotherapy and the need to re-evaluate resource allocation. In other words:



WHAT IS NOT INSURED IS NOT ACCESSIBLE TO ALL

Commissaire à la santé et au bien-être. La Performance du Système de Santé et de Services Sociaux Québécois. 2013. ISBN : 978-2-550-67100-8

International Studies: UK, Australia and France

- So far, the UK and Australia have decided to reimburse psychological therapies in their health systems.
- In the UK, Layard et al.'s (2007) cost-benefit analysis of the program "Improving Access to Psychological Therapies (IAPT)" showed that the program would pay for itself within a period of five years.
- In France, a similar study estimated a cost-benefit ratio ranging between 1.14 and 1.95. Dezetter et al., 2013

Objectives

- The objective of this study was therefore to evaluate the cost-effectiveness associated with rendering psychological services as part of Medicare for individuals with unmet mental health needs.
- This evaluation will provide health system policy informations to help decision makers allocate more optimally resources for a more efficient public managed healthcare system.

Methods

- Using discrete event simulation, we modelled the evolution of depression over a 40 year period to assess the costeffectiveness of increasing publicly funded access to psychological services in Canada as compared to the status quo.
- We included in the model incident cases of depression (2.9% of the population) aged between 20 and 85 years.
- The probability of events and model parameters were based on:
 - epidemiologic, pharmacologic, cost (direct and indirect)
 - and utility data from the literature as well as secondary data analyses of the 2012 CCHS-MH survey carried out by Statistics Canada.

Model overview



RESULTS

 Table 3. Characteristics of a simulated adult population with incident depression over 40 year follow-up.

	Base case scenario: STATUS QUO	Alternate scenario: Increased access to psychological services			
	Average (95%CI) [Per person, over 40 years]				
Number of days depressed	760 (740 - 780)	706 (687 - 725)			
Number of days depressed of non- users of mental health services	91(90 - 92)	81 (80 - 82)			
Number of days being chronically depressed	173 (169 - 177)	157 (153 - 160)			
Number of days of being suicidal	65 (63 - 67)	60 (58 - 62)			
Number of days of well state	12 355 (12 307 – 12 403)	12 476 (12 428 -12524)			
Number of days of well state for non users	140 (138 - 142)	126 (124- 128)			
Prevalence hospitalisation for mental health reasons - lifetime	30.2% (29.8% - 30.5%)	27.9% (27.6% - 28.2%)			
Prevalence of attempted suicide - lifetime	14.6% (14.3% - 14.9%)	14.1% (13.8% - 14.4%)			
Number of suicides	250	184			

Table 4. Cost-effectiveness of increased access to psychological services versus status quo

				\sim
	STATUS QUO	Increased access to	Absolute	ICER
		psychological services	Difference	
	Average (95% CI)			
Total QALYs	30.10 (29.99 - 30.21)	30.27 (30.16 – 30.38)	0.17	
Average health system costs	\$114,123	\$112,519	-\$1,604	'dominant'
Average societal costs with friction cost method	\$118,021	\$ 116,117	-\$1,904	' dominant'
Average societal costs with human capital	\$120,629	\$ 118,039	-\$2,590	'dominant'
approach				
Sensitivity analyses				
Total QALYs, less pessimistic ^a	30.74 (30.64 - 30.84)	30.86 (30.76 – 30.96)	0.18	
Total QALYs, psychotherapy up to 25% less	30.10 (29.99 – 30.21)	30.27 (30.16 – 30.37)	0.17	
effective than previous estimates ^b				
Lower limit estimates				
Average health system costs	\$84,370	\$83,688 ^d	-\$702	'dominant'
Average societal costs with friction cost method	\$85,354	\$84,576 ^d	-\$778	'dominant'
Average societal costs with human capital	\$87,213	\$85,947 ^d	-\$1,266	'dominant'
approach				
Higher limit estimates ^c				
Average health system costs	\$164,088	\$161,018	-\$3,070	'dominant'
Average societal costs with friction cost method	\$197,484	\$191,861	-\$,5623	'dominant'
Average societal costs with human capital	\$200,138	\$193,818	-\$6,320	(dominant'
approach				
^a Less pessimistic: utility for well state = 0.85 and utility of days depressed = 0.58, irrespective of health service use				

^b A recent study reporting that talk therapy may be up to 25% less effective [72]

^cFor individuals receiving care from all three type of professionals, GP/FP, psychiatrist, other MH specialist, all costs related to visits to other MH specialists will be incurred by the health system.

^dFor new individuals accessing publicly funded psychological therapies : number of annual visits is 4 with/without 2 GP visits.
- Rendering psychological services publicly funded for adults with depression reporting an unmet mental health need translates into an average CDN \$123,212,872 (\$67,709,860 to \$190,922,732) in additional costs.
 - [\$1,292 (2 GP/FP visits + 8 psychotherapy sessions within a year) per individual * n = 95,366 individuals with unmet needs]
- The savings to society using the human capital approach would reach on a average of CDN \$246,997,940 (\$120,733,356 to \$602,713,120).

DISCUSSION- In light of literature

- If one were to consider covering psychotherapy sessions for all Canadian adults with incident depression (2.9%), the program costs would reach \$1.008 billion.
- In Australia, in the first 3 years of the Better Access Program, close to 2,017,000 individuals received approximately \$11.1 millions (6 sessions per individual) psychotherapy sessions for a total budget of CDN \$2.80 billion or \$1,514 per individual.^{Pirkis et al., 2015}
- In the UK, the cost of the IAPT program was estimated at £600 million to treat 800,000 patients opting for psychological therapy in 2006.^{Layard et al., 2006}
 - Recently, the NHS invested an additional £400 million in the IAPT program to offer services to children, adolescents, older adults and people with severe mental health and chronic physical problems.^{Thornicroft, 2011}
- In France, the yearly cost of covering 12 psychological sessions for depression and anxiety disorders reached CDN \$729 million, for close to 2.3% of the population.^{Dezetter et al., 2013}
 - This estimate is lower than the one we observed: a psychotherapy session in France costs 41€ (CDN\$65) as opposed to an average of CDN \$145 in Canada.

Implications of covering psychological services as part of Medicare in a public managed healthcare system

In Australia, great concern surrounding the increasing costs of the *Better Access Program* arose, with many arguing that the program was widening the socio-economic gap in mental health service use. ^{Allen, 2011}

Harris et al., (2011) showed:

- that 90% of Better Access users had a 12-month ICD-10 mental disorder;
- those without an affective or anxiety disorder using services were not from higher socio-economic groups;
- and those with a mental disorder received significantly more services than those without.

Implications of covering psychological services as part of Medicare in a public managed healthcare system

Finally, a successful health policy, aimed at improving access to mental health services, that is relevant to a public managed healthcare system, should consider the following (Richards and Bower, 2011):

- Access: Who will get treatment?;
- Equity, type of service offered, cost-effectiveness: Are health outcomes improved at a sustainable cost?
- Patient-centered care: Is the service meeting individual mental health needs?

LIMITATIONS

- The unit cost analyses were based on national data and from the province of Quebec which may limit the generalizability to other countries with publicly funded healthcare systems like Canada.
- We assumed that 8 psychotherapy sessions and 2 physician visits would on average be covered in the increased access to psychological services scenario. Previous publications in Australia have reported that the majority of people use 6 sessions.
 - The sensitivity analyses however did not show significant difference with covering up to 12 psychotherapy sessions.
- Human capital approach was used versus the friction cost method.
- Not everyone with a mental health need would avail themselves to the services and therefore the total costs associated with increased access may have been overestimated.
- The model did not consider the effect of increasing access to psychological services for children and adolescents with mental health problems.
 - the results presented may underestimate the potential benefits and costs saved to society for this population.

CONCLUSION

"Covering psychological services as part of Medicare for individuals with major depression not receiving adequate mental healthcare would pay for itself."

- Canada : every \$1 invested in the program would yield on a average of \$2.00 (\$1.78 to \$3.15) in savings to society.
- UK : IAPT program showed a return on investment reaching £1.75 for every £1 in health expenditures. ^(Layard et al., 2006)
- France : spending €1 in psychological services for people with depression yielded savings of € 1.95 (1.30-2.60) ^(Dezetter et al., 2013)

To put the results of this study into perspective for decision makers:

Public expenditures for mental health and addictions account for only 7.2% of the total national public health budget reaching \$184 per capita. An additional \$3.42 per capita investment in mental health expenditure, representing 0.13% of total health care budget, would lead to a more equitable healthcare system meeting the unmet mental health needs of the Canadian population.

Parameter estimates and cost and utility estimates used in model

 Table 1 a. Parameter estimates: Prevalence estimates of health service use and number of visits (weighted) for mental health

 reasons among individuals with MDE – from analysis of CCHS-MH data and published literature

Variable	Population prevalence	e Visits ; Mean; Median			
Past year health service use for MH reasons: Users	64.3 %				
Past year hospitalisation for MH reasons	29.9%	2; 1			
		LOS : 4 days			
Past year consultation due to suicidal ideation/attempt	81%				
Status Quo: Type of service use among individuals with MDE received	ng adequate care (67.49	%) among users (64.3%)			
			Antidepressant		
			use		
GP/FP only	21.8 %	23, 5			
Psychiatrist only	7.2%	60, 20	81.4%		
GP/FP and psychiatrist	7.8%	11,5; 41, 8			
Other MH specialist only	7.6%	53, 52	47.9%		
GP/FP and Other MH specialist	25.4%	15, 4; 29, 10	90.0%		
Psychiatrist and Other MH specialist	5.1%	19, 6; 22, 11			
GP/FP and Psychiatrist and Other MH specialist	25.1%	9, 4; 15, 4; 17, 9	95.3%		
Status Quo: Type of service use among individuals with MDE NOT receiving adequate care (32.6%) among users (64.3%)					
GP/FP only	38%	4, 2			
Psychiatrist only	3.9%	2, 0	74.2%		
GP/FP and psychiatrist	32.3%	2, 2; 3, 3			
Other MH specialist only	5.7%	3, 2	5.7%		
GP/FP and Other MH specialist	14.8%	3, 3			
Psychiatrist and Other MH specialist	-	-	18.9%		
GP/FP and Psychiatrist and Other MH specialist	4.1%	2, 2; 3, 3			
Comparator: Increased access to psychological services – publicly funded – for MDE with unmet need					
Past year health service use for MH reasons	68.8%				
Adequate care among users	74.8%				
New users with unmet mental health need receiving adequate care	8.1%				

Length of 5 th MDE Episode20 weeksProbability of persistent MDE Episode in 2 nd year62%Probability of persistent MDE Episode in 3 rd year73%Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression84%Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeksLength of 2 nd MDE Episode untreated17 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated31 weeksLength of 3 rd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.7Length of 5 th - 9 th episode untreated0.7Probability of 3 rd MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other54%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other54%MH specialist and antidepressant57%Non Adequate Treatment	Variable	Base Case Values	Source or reference	
Persistent MDE into following year20%[41]Past year attempted suicide among MDE not using or receiving adequate mental health care9.13% (8.76% - 8.98%)[42]Past year attempted suicide among MDE receiving adequate mental health care6.80% (6.74% - 6.92%)[42]Risk of repeat suicide attempt following attempt Median estimatesYear 1 = 16%[43,44]Year 1 = 16%Year 4 = 23%[45,47]Risk of Suicide following attempt Median estimatesYear 1 = 1.8%; (45,47][45,47]TREATED Major Depression132 weeks[46,49]Length of 2 nd MDE Episode (i.e. time to relapse)132 weeks[46,49]Length of 3 nd MDE Episode21 weeks[48,49]Length of 3 nd MDE Episode21 weeks[48,49]Length of 3 nd MDE Episode21 weeks[48,49]Length of 5 th MDE Episode20 weeks[48,49]Length of 5 th MDE Episode21 weeks[48,49]Length of 5 th MDE Episode in 2 nd year73%1Probability of persistent MDE Episode in 3 nd year34%1Untreated Major Depression62%1Length of 3 nd MDE Episode untreated29 weeks[48,51]Length of 3 nd MDE Episode untreated0.51Length of	Health states / Events			
Past year attempted suicide among MDE not using or receiving adequate mental health care9.13% (8.76% – 8.98%)[42]Past year attempted suicide among MDE receiving adequate mental health care6.80% (6.74% – 6.92%)[42]Risk of repeat suicide attempt following attempt Median estimatesYear 1 = 16%Year 1 = 16%Year 1 = 1.23%;Year 1 = 1.23%;[45.47]Risk of Suicide following attempt Median estimatesYear 1 = 1.83;[45.47]TEKATED Major DepressionYear 1 = 1.83;[45.47]Time to 2 ^m , 3 rd MDE Episode (i.e. time to relapse)132 weeksFeeddaLength of 1 rd MDE Episode20 weeks19 weeks[48.49]Length of 3 rd MDE Episode in 2 rd yearC62%73%[48.49]Probability of persistent MDE Episode in 3 rd year20 weeks[48.49]Untreated Major Depression84%[48.49][48.49]Length of 2 rd MDE Episode in 3 rd year73%[48.49]Untreated Major Depression17 weeks[48.49]Length of 2 rd MDE Episode in 4 rd year20 weeks[48.49]Length of 2 rd MDE Episode untreated17 weeks[48.49]Length of 2 rd MDE Episode untreated20 weeks[48.49]Length of 2 rd MDE Episode untreated20 weeks[48.49]Length of 2 rd MDE Episode untreated17 weeks[48.49]Length of 2 rd MDE Episode untreated0.5[48.49]Length of 2 rd MDE Episode untreated0.5[48.49]Length of 2 ^{rdi} MDE Episode untreated0.5[48.49]Length of 2	Incidence of major depression	2.9%	[40]	
Past year attempted suicide among MDE receiving adequate mental health care6.80% (6.74% - 6.92%)[42]Risk of repeat suicide attempt following attempt Median estimatesYear 1 = 16% Year 1 = 13%;[43,44]Risk of Suicide following attempt Median estimatesYear 1 = 16% Year 1 = 1.8%;[43,44]Risk of Suicide following attempt Median estimatesYear 1 = 1.8%;[45.47]TREATED Major DepressionTime to 2", 3" and MDE Episode21 weeks[45.47]Length of 1 st MDE Episode21 weeks[48,49][48,49]Length of 3" MDE Episode21 weeks[48,49]Length of 3" MDE Episode in 2" year62%[48,49]Length of 5 th MDE Episode in 3" year73%73%Probability of persistent MDE Episode in 3" year84%[48,49]Length of 3" MDE Episode in 4 th year84%[48,49]Length of 3" MDE Episode in 4 th year20 weeks[48,49]Length of 3" di DE Episode in 4 th year84%[48,49]Length of 3" MDE Episode untreated17 weeks[48-51]Length of 3 th MDE Episode untreated22 weeks[48-51]Length of 3 th MDE Episode untreated0.5[48-51]Length of 3 th MDE Episode untreated0.5[48-51]Length of 3 th MDE Episode untreated0.5[48-51]Length of 3 th MDE Episode untreated0.5[52]Probability of 2 th MDE Episode untreated0.5[52]Probability of 3 th MDE Episode untreated0.5[52]Probability of 3 th MDE Episode untreated0.5 </td <td>Persistent MDE into following year</td> <td>20%</td> <td>[41]</td>	Persistent MDE into following year	20%	[41]	
Risk of repeat suicide attempt following attempt Median estimatesVear 1 = 16% Year1 to 4 = 21%; Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 = 16%; Year1 to 2 = 20% Year1 = 16%; Year1 =	Past year attempted suicide among MDE not using or receiving adequate mental health care	9.13% (8.76% – 8.98%)	[42]	
Year1 to 4 -21%; Year 3 4 -21%; Year 4 - 23%[43,44] Year 3 4 -23%Risk of Suicide following attempt Median estimatesYear 4 - 23%[45-47]TREATED Major DepressionTime to 2 ^m , 3 rd MDE Episode (i.e. time to relapse)132 weeksFreedom 132 weeksLength of 1 st MDE Episode (i.e. time to relapse)21 weeksFreedom 132 weeksFreedom 132 weeksLength of 1 st MDE Episode20 weeks20 weeksFreedom 193 weeksLength of 3 rd MDE Episode20 weeks20 weeksFreedom 193 weeksLength of 5 th MDE Episode in 2 nd year62%73%Freedom 193 weeksProbability of persistent MDE Episode in 2 nd year73%Freedom 193 weeks48 weeksUntreated Major Depression17 weeks48 weeks[48,49]Length of 3 rd MDE Episode in 2 nd year73%Freedom 193 weeks48 weeksProbability of persistent MDE Episode in 2 nd year73%Freedom 193 weeks48 weeksLength of 3 rd MDE Episode untreated29 weeks48 weeks[48,49]Length of 3 rd MDE Episode untreated31 weeks[48-51]Length of 3 rd MDE Episode untreated0.5Freedom 193 weeks[48-51]Length of 3 rd MDE Ep	Past year attempted suicide among MDE receiving adequate mental health care	6.80% (6.74% – 6.92%)	[42]	
TREATED Major DepressionIterationTime to 2 nd , 3 nd MDE Episode (i.e. time to relapse)132 weeksLength of 1 nd MDE Episode21 weeksLength of 2 nd MDE Episode20 weeksLength of 3 nd MDE Episode19 weeksLength of 3 nd MDE Episode20 weeksLength of 5 th MDE Episode20 weeksLength of 5 th MDE Episode20 weeksLength of 5 th MDE Episode20 weeksProbability of persistent MDE Episode in 2 nd year62%Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression73%Time to 2 nd , 3 rd MDE Episode untreated29 weeksLength of 3 nd MDE Episode untreated29 weeksLength of 3 nd MDE Episode untreated29 weeksLength of 3 nd MDE Episode untreated20 weeksLength of 3 nd MDE Episode untreated22 weeksLength of 3 nd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; GP/FP and psychiatrist and other67%MH specialist ond67%Non Adequate Treatment Arm: Recovery51	Risk of repeat suicide attempt following attempt Median estimates	Year1 to 4 =21%;	[43,44]	
Time to 2nd, 3rd MDE Episode (i.e. time to relapse)132 weeksLength of 1st MDE Episode21 weeksLength of 2nd MDE Episode20 weeksLength of 3rd MDE Episode19 weeksLength of 3rd MDE Episode20 weeksLength of 4th MDE Episode20 weeksLength of 4th MDE Episode20 weeksProbability of persistent MDE Episode in 2nd year62%Probability of persistent MDE Episode in 3rd year73%Probability of persistent MDE Episode in 4th year84%Untreated Major Depression17 weeksTime to 2nd, 3rd MDE Episode untreated17 weeksLength of 4th MDE Episode untreated29 weeksLength of 3rd MDE Episode untreated31 weeksLength of 3rd MDE Episode untreated0.5Length of 3rd MDE Episode untreated0.5Probability of 3rd MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and ther MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist only67%Non Adequate Treatment Arm: Recovery54%[54]Non Adequate Treatment Arm: Recovery54%	Risk of Suicide following attempt Median estimates	Year 1 = 1.8% ;	[45-47]	
Length of 1 st MDE Episode21 weeksLength of 2 nd MDE Episode20 weeksLength of 3 rd MDE Episode19 weeksLength of 3 rd MDE Episode21 weeksLength of 5 th MDE Episode20 weeksProbability of persistent MDE Episode in 2 nd year62%Probability of persistent MDE Episode in 3 rd year73%Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression73%Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeksLength of 3 rd MDE Episode untreated17 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated31 weeksLength of 3 rd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.7Length of 3 rd MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other G7%[51MH specialist only67%MH specialist and antidepressant7%Non Adequate Treatment Arm: Recovery67%	TREATED Major Depression			
Length of 2nd MDE Episode20 weeksLength of 3rd MDE Episode19 weeksLength of 4th MDE Episode21 weeksLength of 5th MDE Episode20 weeksProbability of persistent MDE Episode in 2nd year62%Probability of persistent MDE Episode in 3rd year73%Probability of persistent MDE Episode in 4th year84%Untreated Major Depression48 weeksTime to 2nd, 3rd MDE Episode untreated17 weeksLength of 3th MDE Episode untreated29 weeksLength of 3th MDE Episode untreated31 weeksLength of 3th MDE Episode untreated31 weeksLength of 3th MDE Episode untreated0.5Probability of 2nd MDE Episode untreated0.7Length of 3th MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist only67%	Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)	132 weeks		
Length of 3rd MDE Episode19 weeks[48,49]Length of 5th MDE Episode20 weeks[48,49]Length of 5th MDE Episode20 weeks62%Probability of persistent MDE Episode in 3rd year73%73%Probability of persistent MDE Episode in 4th year84%14%Untreated Major Depression84%[48,49]Length of 3rd MDE Episode untreated17 weeks[48,49]Length of 3rd MDE Episode untreated29 weeks[48,51]Length of 3th MDE Episode untreated22 weeks[48-51]Length of 5th - 9th episode untreated0.5[48-51]Length of 5th MDE Episode untreated0.5[51]Probability of 2rd MDE Episode untreated0.9[52]Probability of 3rd MDE Episode untreated0.9[53]Probability of 4th and 5th MDE Episode untreated0.9[53]Adequate treatment Recovery (one lifetime episode) within year[54][54]GP/FP and phychiatrist, and other MH specialist; GP/FP and phychiatrist and o	Length of 1 st MDE Episode	21 weeks		
Length of 4 th MDE Episode21 weeks[48,49]Length of 5 th MDE Episode in 2 nd year20 weeks62%Probability of persistent MDE Episode in 3 rd year73%62%Probability of persistent MDE Episode in 4 th year84%48%Untreated Major Depression84%[48,49]Length of 2 nd MDE Episode (i.e. time to relapse)48 weeks[48,49]Length of 3 rd MDE Episode untreated177 weeks[48.51]Length of 3 rd MDE Episode untreated29 weeks[48.51]Length of 3 rd MDE Episode untreated0.5[48.51]Length of 3 rd MDE Episode untreated0.5[53.55]Probability of 4 rd MDE Episode untreated0.9[53.55]Probability of 4 rd MDE Episode untreated63%[53.55]Other MH specialist only63%[53.55]Other MH specialist and antidepressant67%[51]MH specialist and antidepressant67%[51]MH specialist and antidepressant67%[51]	Length of 2 nd MDE Episode	20 weeks		
Length of 5 th MDE Episode20 weeksProbability of persistent MDE Episode in 2 nd year62%Probability of persistent MDE Episode in 3 rd year73%Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression84%Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeksLength of 3 rd MDE Episode untreated17 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5Probability of 4 th and 5 th MDE Episode untreated0.5GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other54%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other57%MH specialist and antidepressant67%[5]MH specialist and antidepressant <t< td=""><td>Length of 3rd MDE Episode</td><td>19 weeks</td><td></td></t<>	Length of 3 rd MDE Episode	19 weeks		
Probability of persistent MDE Episode in 2 nd year62%Probability of persistent MDE Episode in 3 rd year73%Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression84%Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeksLength of 2 nd MDE Episode untreated17 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 5 th - 9 th episode untreated31 weeksLength of 2 nd MDE Episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist and antidepressant67%Non Adequate Treatment Arm: Recovery54[55]	Length of 4 th MDE Episode	21 weeks	[48,49]	
Probability of persistent MDE Episode in 3rd year73%Probability of persistent MDE Episode in 4th year84%Untreated Major Depression1Time to 2nd, 3rd MDE Episode (i.e. time to relapse)48 weeksLength of 2nd MDE Episode untreated17 weeksLength of 3rd MDE Episode untreated29 weeksLength of 3rd MDE Episode untreated31 weeksLength of 3rd MDE Episode untreated31 weeksLength of 3rd MDE Episode untreated0.5Probability of 2nd MDE Episode untreated0.5Probability of 2nd MDE Episode untreated0.7Length of 3rd MDE Episode untreated0.5Probability of 2nd MDE Episode untreated0.5Probability of 3rd MDE Episode untreated0.5Probability of 4th and 5th MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist; only54%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist and antidepressant67%MH specialist and antidepressant67%[55]MH specialist and antidepressant67%[55]	Length of 5 th MDE Episode	20 weeks		
Probability of persistent MDE Episode in 4 th year84%Untreated Major Depression1Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeksLength of 2 nd MDE Episode untreated17 weeksLength of 3 rd MDE Episode untreated29 weeksLength of 3 rd MDE Episode untreated31 weeksLength of 5 th - 9 th episode untreated31 weeksLength of 5 th - 9 th episode untreated0.5Probability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.7Probability of 3 rd MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist; GP/FP	Probability of persistent MDE Episode in 2 nd year	62%		
Untreated Major DepressionImage: Constraint of the second of	Probability of persistent MDE Episode in 3 rd year	73%		
Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)48 weeks[48,49]Length of 2 nd MDE Episode untreated17 weeks17 weeks148.49]Length of 3 rd MDE Episode untreated29 weeks29 weeks148.51]Length of 4 th MDE Episode untreated31 weeks148.51]148.51]Length of 5 th - 9 th episode MDE Episode untreated0.5169.55]169.55]Probability of 2 nd MDE Episode untreated0.7152.55]159.55]Probability of 4 th and 5 th MDE Episode untreated0.9153.55]159.55]Other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and antidepressant67%153.55]MH specialist and antidepressant67%155.55]159.55]MH specialist and antidepressant67%155.55]MH specialist and antidepressant67%155.55]	Probability of persistent MDE Episode in 4 th year	84%		
Length of 2 nd MDE Episode untreated17 weeks17 weeksLength of 3 rd MDE Episode untreated29 weeks29 weeksLength of 4 th MDE Episode untreated31 weeks148-51Length of 5 th - 9 th episode MDE Episode untreated0.522 weeksProbability of 2 nd MDE Episode untreated0.57Probability of 3 rd MDE Episode untreated0.75Probability of 4 th and 5 th MDE Episode untreated0.95Adequate treatment Recovery (one lifetime episode) within year63%53-55Other MH specialist only54%54GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%55MH specialist and antidepressant67%55MH specialist and antidepressant67%55	Untreated Major Depression			
Length of 3rd MDE Episode untreated29 weeks29 weeksLength of 4th MDE Episode untreated31 weeks[48-51]Length of 5th - 9th episode MDE Episode untreated22 weeks22 weeksProbability of 2nd MDE Episode untreated0.5	Time to 2 nd , 3 rd MDE Episode (i.e. time to relapse)	48 weeks	[48,49]	
Length of 4 th MDE Episode untreated31 weeks[48-51]Length of 5 th - 9 th episode MDE Episode untreated22 weeks22Probability of 2 nd MDE Episode untreated0.552Probability of 3 rd MDE Episode untreated0.7[52]Probability of 4 th and 5 th MDE Episode untreated0.954Adequate treatment Recovery (one lifetime episode) within year63%[53-55]Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other MH specialist and antidepressant67%[55]MH specialist and antidepressant67%[55]Non Adequate Treatment Arm: Recovery6154	Length of 2 nd MDE Episode untreated	17 weeks		
Length of 4 th MDE Episode untreated31 weeksLength of 5 th - 9 th episode MDE Episode untreated22 weeksProbability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.7Probability of 4 th and 5 th MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year63%GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%Other MH specialist only54%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and otherMH specialist and antidepressant67%Non Adequate Treatment Arm: Recovery61	Length of 3 rd MDE Episode untreated	29 weeks		
Probability of 2 nd MDE Episode untreated0.5Probability of 3 rd MDE Episode untreated0.7[52]Probability of 4 th and 5 th MDE Episode untreated0.95Adequate treatment Recovery (one lifetime episode) within year55GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%[53-55]Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressant67%[55]Non Adequate Treatment Arm: Recovery555	Length of 4 th MDE Episode untreated	31 weeks	[48-51]	
Probability of 3rd MDE Episode untreated0.7[52]Probability of 4th and 5th MDE Episode untreated0.90.9Adequate treatment Recovery (one lifetime episode) within year0.90.9GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%[53-55]Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressant67%[55]Non Adequate Treatment Arm: Recovery67%155]	Length of 5 th - 9 th episode MDE Episode untreated	22 weeks		
Probability of 4th and 5th MDE Episode untreated0.9Adequate treatment Recovery (one lifetime episode) within year6GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%Other MH specialist only54%GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%MH specialist and antidepressant67%Non Adequate Treatment Arm: Recovery6	Probability of 2 nd MDE Episode untreated	0.5		
Adequate treatment Recovery (one lifetime episode) within yearAdequate treatment Recovery (one lifetime episode) within yearGP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%[53-55]Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressant67%[55]Non Adequate Treatment Arm: Recovery67%1	Probability of 3 rd MDE Episode untreated	0.7	[52]	
GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant63%[53-55]Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressant67%[55]Non Adequate Treatment Arm: Recovery67%54%	Probability of 4 th and 5 th MDE Episode untreated	0.9		
Other MH specialist only54%[54]GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressant67%100Non Adequate Treatment Arm: Recovery67%100	Adequate treatment Recovery (one lifetime episode) within year			
GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other67%[55]MH specialist and antidepressantNon Adequate Treatment Arm: Recovery67%10%	GP/FP only, psychiatrist only, GP/FP and psychiatrist, antidepressant	63%	[53-55]	
MH specialist and antidepressant Non Adequate Treatment Arm: Recovery	Other MH specialist only	54%	[54]	
Non Adequate Treatment Arm: Recovery	GP/FP and other MH specialist; psychiatrist and other MH specialist; GP/FP and psychiatrist and other	67%	[55]	
	MH specialist and antidepressant			
Not Adequate antidepressant and health service use for mental health reasons with any physician $24\% - 30\%$ [54]	Non Adequate Treatment Arm: Recovery			
	Not Adequate antidepressant and health service use for mental health reasons with any physician	24% - 30%	[54]	
Not Adequate health service use with other MH specialist only 25% [54,55]	Not Adequate health service use with other MH specialist only	25%	[54,55]	
Spontaneous recovery without treatment 30% [23]	Spontaneous recovery without treatment	30%		
Relapse among those presenting spontaneous recovery without treatment44%[23]	· · ·	44%		
Length of antidepressant use median 365 days use [56]	Length of antidepressant use	median 365 days use		
Persistent antidepressant use among incident users: at 1 month, 3 months, 6 months, 1 year and 2 73%, 59%, 46%, 33%, 22% [57] years (and extrapolated to 3 years)		73%, 59%, 46%, 33%, 22%	[57]	

Table 2. Cost and utility estimates used in model

Utilities for events/health states ^a	Base case Value (range)	
Well/Recovery	0.85	[27]
Well/Recovery in non-health service users ^b	0.72	
Depressed among health service users (moderate	0.33	[58]
depression)		
Dysthymia/chronic depression (partial remission)	0.58	[27,58]
Suicidal (severe depression)	0.09	[61-62]
Depressed, non-health service users	0.30	[58-60]
Dead	0	[61]
Utility decrement associated with antidepressant use	-0.005	[27,62]
Costs (in 2013 dollars)		
Health system costs		
Annual healthcare costs: Healthy/well state (i.e. non	\$2735 (\$2141, \$3497)	[63]
depressed and non-suicidal)	Ş2755 (Ş2141, Ş5497)	
Per diem hospitalisation cost	\$1084	[64]
Annual healthcare costs: Depression	\$3647 (\$2854, \$4662)	[65]
Excess costs associated with antidepressant use	\$1980 (\$426 <i>,</i> \$2232)	[32]
Annual healthcare costs: Suicidal cases	\$8303 (\$1838 <i>,</i> \$45 188)	
Healthcare costs: Attempted suicide	\$14 229 (\$2042 <i>,</i> \$45 909)	[66]
Healthcare and related costs: Suicide	\$26 270 (\$10 492, \$108 230)	
Indirect costs related to lost productivity		
Cost of short term disability	\$18 689 (\$16 693 <i>,</i> \$20 685)	[67-69]
Absenteeism and presenteeism costs	\$2382 (0 - \$27 516)	[70]
Friction cost method: average replacement is 3 months	\$10 163 (\$3387, \$40 653)	[66,71]
(range 1 and 12 months)	ştu tos (şss87, ş40 053)	
Human capital approach	\$729 314 (\$515 886, \$772 406)	
^a Utility values were all based on the EO ED EI		

^a Utility values were all based on the EQ-5D-5L

^b Utility values associated with the well/recovery state are associated with a slightly lower utility given that relapse rates are higher in non-users

References

- CCHS 2012 MH: <u>https://www.canada.ca/en/public-health/services/chronic-diseases/mental-illness/what-depression.html</u>
- Greenberg PE, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155-62.
- Myhr G, Payne K. Cost-Effectiveness of CBT for mental disorders: Implications for public care funding policy in Canada. CJP 2006; 51:662-70.
- Wells KB, et al. The cumulative effects of quality improvement for depression on outcome disparities over 9 years: results from a randomized, controlled group-level trial. Med Care 2007; 45:1052-1059.
- Canadian Network for Mood and Anxiety Treatments (CANMAT). Guidelines for the Diagnosis and Pharmacological Treatment of Depression. 1st ed. Revised. Toronto, On: CANMAT 1999. 76 pp.
- Vasiliadis HM, et al. Service use for mental health reasons: cross-provincial differences in rates, determinants, and equity of access. Can J Psychiatry 2005; 50: 614–619.
- Grenier J, et al. <u>Collaboration between family physicians and psychologists: what do family physicians know about psychologists' work?</u> Can Fam Physician 2008; 54:232-233.
- Vasiliadis HM, Tempier R, Lesage A, Kates N. General practice and mental health care: determinants of outpatient service use. Can J Psychiatry 54:468-76, 2009.
- Chartier-Otis M, et al. Determinants of barriers to treatment for anxiety disorders. Psych Q 2010;81:127-138.
- Vasiliadis HM, et al. Do Canada and the United States differ in prevalence of depression and utilization of services? Psychiatr Serv. 2007; 58:63-71.

References

- Sunderland A, Findlay LC. Perceived need for mental health care in Canada: Results from the 2012 Canadian Community Health Survey-Mental Health. Health Rep 24:3-9, 2013.
- Layard R., et al. Cost-benefit analysis of psychological therapy. Nat Institute Econ Review 202:90-98, 2007.
- Layard R. The case for psychological treatment centres. BMJ 332:1030-1032, 2006.
- Dezetter A, Briffault X, Ben Lakhdar C, Kovess-Masfety V. Costs and benefits of improving access to psychotherapies for common mental disorders. J Ment Health Policy Econ 16:161-177, 2013.
- Allen NB, Jackson HJ. What kind of evidence do we need for evidence-based mental health policy? The case of the Better Access initiative. Aust N Z J Psychiatry 45:696-699, 2011.
- Harris MG, Burgess PM, Pirkis JE, Slade TN, Whiteford HA. Policy initiative to improve access to psychological services for people with affective and anxiety disorders: population-level analysis. Br J Psychiatry 198:99-108, 2011.
- Richards DA, Bower P. Equity of access to psychological therapies. Br J Psychiatry 198:91-92, 2011.
- Pirkis J, Harris M, Hall W, Ftanou M. Evaluation of the Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule Initiative. Centre for health policy, programs and economics. 2011. Accessed January 17, 2015: <u>http://www.ozfoodnet.gov.au/internet/main/publishing.nsf/Content</u> /5F330C940AFDB767CA257BF0001DE702/\$File/sum.pdf



Commission de la santé mentale du Canada

Thank you!

Lara di Tomasso, Research and Policy Analyst lditomasso@mentalhealthcommission.ca

Dr. Karen Cohen, Canadian Psychological Association <u>KCohen@cpa.ca</u>

Dr. Helen-Maria Vasiliadis, University of Sherbrooke

Helen-Maria.Vasiliadis@USherbrooke.ca

Dr. Giorgio Tasca, University of Ottawa

gtasca@uottawa.ca

✓ @MHCC_ f/theMHCC

☑ @theMHCC ► /1MHCC in /Mental Health Commission of Canada